Currently set to Index
Currently set to Follow

Portfolio

Scopio

Revolutionizing diagnostic procedures by providing end-to-end digital cytology solutions thereby helping clinics of all sizes embrace digital innovation and unlock diagnostic insights.

Ceidos

C-Netics is an innovative lab device to fully automatize cell expansion monitoring in a closed system, ensuring better outcomes for a much lower price.

ClearCut Medical

ClearCut Medical has developed a novel, portable imaging system platform bringing the power and trust of MRI into the operating room

Neteera

Continuous, contactless, passive vital signs and bio-data monitoring solution that eliminates the need for device manipulation, removal of clothing, and caregiver presence.

Neurocare

The company delivers personalized treatment for a range of mental health treatment areas in a unique Digital Therapy Platform (DTP).

Cardiolyse

Cardiolyse is a cloud ECG & HRV analytics platform

This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de

Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.

I agree

Vivior

Personalized Vision Performance: The first “Fitbit for the eyes”

This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de

Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.

I agree

Medikura (XO Life)

The real-world evidence platform for the efficacy and safety of drugs

This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de

Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.

I agree

Emperra

Fighting the diabetes pandemic with a telemedicine solution

Munevo

Venture Category: MedTech

Smartglasses helping people with disabilities to achieve independent mobility

Surge-on Medical

Venture Category: MedTech
Business Phase: Sales Expansion
Professional Investors: 1 VC, 2 Family Offices

Lipozyt Marker

Diagnostic tests for the personalized treatment of type 2 diabetes

This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de

Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.

I agree

Deal Showcase: Scopio Labs

Investment Category:
Outcome Booster

Investment Case:
Blood is one of the most foundational gateways to health information. Roughly 120,000 laboratories worldwide conduct 600 million PBS tests annually for the global population, predominantly via manual microscopes. Even with the adoption of digital tools, today’s solutions do not showcase all required regions of interest in a PBS slide, only capturing snapshots of cells. Consequently, technologists frequently default to the manual microscope for a more detailed examination of the raw data.

Company Profile:
Scopio Labs, Tel Aviv, co-founded by Itai Hayut and Erez Na’aman in 2015, is dedicated to unlocking the potential of imaging and AI in hematology, redefining diagnostics and related drug development by championing Full Field Morphology (FFM) at scale. Uncovering actionable insights from vast amounts of data readily available in the average blood sample and bone marrow aspirate, Scopio’s solutions will showcase thousands of cells at scale in high resolution, to enable new hematology diagnostic methods.

Using advanced computational photography imaging and tailored AI tools, Full Field PBS gives clinical laboratories an unprecedented ability to capture digital scans with full field view of the monolayer and feathered edge at 100X oil immersion resolution level. The Full Field PBS utilizes adaptive monolayer identification in support of long and short smears and automates the analysis process by pre-classifying 200 white blood cells (WBC), providing platelet pre-estimate, and enabling RBC morphology evaluation.

Investment Rationale
Recent advances in GPU technology (Graphic processor units) will help the company to achieve its vision in a cost- effective and timely manner. The combination of full-field high-resolution images with an AI-driven platform can be the breakthrough towards full digitalization in this field.

Invest in Health

Powerful Partner: EIT Health

EIT Health leverages the expertise of over 135 member organisations from the pharmaceutical, diagnostics, and medical technology fields, as well as insurance groups, payers, research institutes, and universities.

Learn more

For Startups: Apply Now

Would you like to finance and market your business idea through aescuvest? Please send us the key information about your company or project application template. If your profile is approved, you can start your own funding in healthcare.

Apply now

Independent experts ensure excellence

The assessment by the Investment Committee is the linchpin for project approval. The committee’s decisions are always preceded by an analysis whereby the pros and cons are carefully weighed. Negative decisions are always binding.

Learn how

Successfully funded on our sister platform aescuvest.de

IMMUNOLOGIK 2

ImmunoLogik has developed an innovative lead candidate for the efficient and vital treatment of HIV patients who have already explored all other modern therapies.

This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de

Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.

I agree

SNAKE FX

nice!innovations has developed an innovative external fixator, the ‘SnakeFX’. The startup decided to finance it by crowdfunding in order to develop the prototype to market maturity.

This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de

Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.

I agree

LIQUI-PATCH

Traditional drug delivery patches are being replaced: Epinamics sprayable invisible film allows a convenient, discreet and gentle application to the skin.

This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de

Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.

I agree

Medikura (XO Life)

The real-world evidence platform for the efficacy and safety of drugs

This investment opportunity is brokered by aescuvest GmbH on our independent platform aescuvest.de

Legal notice according to the German Capital Investments Act (VermAnlG): This investment carries considerable risks and may lead to an entire loss of the assets invested. The expected yield is not guaranteed and may be lower.

I agree

Neurocare

The company delivers personalized treatment for a range of mental health treatment areas in a unique Digital Therapy Platform (DTP).

Funded %

Neteera

Continuous, contactless, passive vital signs and bio-data monitoring solution that eliminates the need for device manipulation, removal of clothing, and caregiver presence.

Funded %

ClearCut Medical

ClearCut Medical has developed a novel, portable imaging system platform bringing the power and trust of MRI into the operating room

Funded %

Ceidos

C-Netics is an innovative lab device to fully automatize cell expansion monitoring in a closed system, ensuring better outcomes for a much lower price.

Funded %

Scopio

Revolutionizing diagnostic procedures by providing end-to-end digital cytology solutions thereby helping clinics of all sizes embrace digital innovation and unlock diagnostic insights.

Funded %

Get notified

of new campaigns and news.
We do not sell or share your data to third parties. View our Privacy notice

By clicking on 'Sign up', you agree to receive the newsletter with information on, for example, our services, our company as well as to its analysis through individual measurement, storage and evaluation of opening rates and click rates in recipient profiles for the purpose of designing future newsletters according to the interests of our readers. Consent can be revoked with effect for the future. Detailed information is available in our data privacy terms.